Anaplastic astrocytoma
Rare brain cancer, WHO grade 3, IDH-mutated.
Nephron · CC BY-SA 3.0
Anaplastic astrocytoma is an older name for a rare brain cancer, now classified as a WHO grade 3 IDH-mutated astrocytoma. In the U.S., about 0.35 people per 100,000 are diagnosed each year.
**Signs and symptoms** Symptoms depend on where the tumor sits in the brain. Focal issues can include weakness, vision problems, trouble speaking, or difficulty walking. More general symptoms involve personality changes, headaches, nausea, and seizures. The time from first symptom to diagnosis varies widely, but clinical literature often notes a shorter or more variable period than previously thought. Seizures are less common with anaplastic astrocytomas than with low-grade tumors.
**Causes** The best-known risk factor is ionizing radiation, with CT scans being a notable source. However, the exact risk increase per unit of low-dose radiation is not a widely established canonical figure for this specific tumor type. Most high-grade gliomas appear without a clear cause, but fewer than 5% of people with malignant astrocytoma have a known or suspected inherited condition. These include neurofibromatosis type I, Li-Fraumeni syndrome, and tuberous sclerosis. Previous exposure to vinyl chloride or high-dose radiation therapy to the brain has also been linked to these tumors.
**Pathology**
*Histology* About three-quarters of anaplastic astrocytomas contain both low- and high-grade areas, suggesting they evolved from a lower-grade precursor; the rest arise on their own. Under the microscope, the tumor shows increased cell density and abnormal nuclei, along with brisk mitotic activity—this is the key feature that separates grade 3 from grade 2. It also expresses glial markers like GFAP but not neuronal markers. Importantly, it lacks microvascular proliferation and necrosis (which, along with a homozygous CDKN2A/B deletion, would define grade 4). The MIB-1 (Ki-67) labeling index typically ranges from 5% to 10%, though it can overlap with both low-grade astrocytoma and glioblastoma. Histologic grading alone is not very reproducible among pathologists and doesn't always predict outcome well; molecular classification is now considered a stronger predictor, and combining both approaches gives the most accurate assessment.
*Molecular features* No single molecular marker defines anaplastic astrocytoma.
Quick Facts
- Specialty
- Neuro-oncology, Neurosurgery
- Prognosis
- 23.6% (5-year survival)
Facts from the source article.
Lore & Background
Anaplastic astrocytoma frequently contains mixed areas of low and high grade tumor, reflecting progression from a lower-grade precursor in three quarters of cases; the remaining quarter arise de novo. Histologically, it is characterized by increased cellularity, nuclear atypia, brisk mitotic activity, and absence of microvascular proliferation and necrosis. The MIB-1 (Ki-67) labelling index is usually 5–10% but may overlap with both low-grade astrocytoma and glioblastoma.
Reader's Guide
The term anaplastic astrocytoma is now considered outdated under the 2021 WHO classification, which redefines these tumors as astrocytoma, IDH-mutant, WHO grade 3. Molecular features are critical: IDH1/IDH2 mutations define the parent classification, with IDH1 mutated in 95% of cases. MGMT promoter methylation occurs in about 50% of cases and is associated with improved progression-free survival. The presence of CDKN2A/B deletion indicates grade 4, and 1p/19q codeletion reclassifies the tumor as oligodendroglioma. Standard treatment involves maximal safe surgical resection followed by radiation therapy and adjuvant temozolomide. Prognosis is poor, with a 5-year relative survival rate of 23.6% and median survival of 2–3 years. Younger age, female sex, treatment after 2000, and surgery are associated with improved survival.
Did You Know?
- The annual incidence rate in the United States is 0.35 per 100,000 people.
- Exposure to ionizing radiation is a known risk factor, but the exact risk increase per 100 milligray is not a widely established canonical figure for this specific tumor type.
- Three quarters of anaplastic astrocytomas progress from a lower-grade precursor.
Clinical Presentation & Diagnostic Journey
Anaplastic astrocytoma, now understood as a WHO grade 3 IDH-mutated astrocytoma, remains a rare malignancy with an annual incidence of roughly 0.35 cases per 100,000 people in the United States. Patients typically present with a mix of focal and generalized neurological symptoms that depend heavily on where the tumor sits within the brain. Focal manifestations can include progressive weakness, visual field deficits, language difficulties, and unsteady gait, while generalized complaints often involve shifts in personality or behavior, persistent headaches, nausea, and seizures. Notably, seizures occur less frequently in anaplastic astrocytoma than in lower-grade astrocytomas. The interval from first symptom to formal diagnosis averages one and a half to two years, though this window is highly variable and sits between the slower trajectory of low-grade tumors and the rapid course of glioblastomas. Among identifiable risk factors, ionizing radiation stands out, with an estimated 115 percent increase in risk per 100 milligray of exposure. A small minority of cases—fewer than five percent—trace back to hereditary syndromes such as neurofibromatosis type I, Li-Fraumeni syndrome, hereditary nonpolyposis colorectal cancer, or tuberous sclerosis.
Pathological & Molecular Classification
Under the microscope, anaplastic astrocytoma reveals a tissue architecture that frequently blends low-grade and high-grade regions, a pattern reflecting progression from a lower-grade precursor in roughly three-quarters of cases; the remaining quarter appear to arise de novo. Key histologic hallmarks include elevated cellularity, pronounced nuclear atypia, and brisk mitotic activity—the last being the critical feature separating grade 3 from grade 2 astrocytomas. Glial markers such as GFAP are present while neuronal markers are absent, and crucially, neither microvascular proliferation nor necrosis is seen; those features, together with homozygous CDKN2A/B deletion, would push the classification to grade 4. The Ki-67 proliferation index typically falls between five and ten percent, though it overlaps with both lower-grade tumors and glioblastoma. On the molecular front, no single marker defines the entity. IDH1 mutations appear in approximately 95 percent of cases and confer a significantly better outcome than IDH-wildtype tumors. MGMT promoter methylation, found in about half of cases, correlates with improved progression-free survival. Under the 2021 WHO framework, the absence of 1p/19q codeletion is required—its presence would reclassify the tumor as an oligodendroglioma—and the absence of CDKN2A/B deletion is essential to maintain the grade 3 designation.
Treatment & Rehabilitation
The cornerstone of initial management is surgical resection, with the goal of removing as much tumor as safely possible without inflicting additional neurological deficits. Radiation therapy is a standard adjunct, having demonstrated the ability to prolong survival. For patients whose disease recurs, long-term follow-up data support the use of adjuvant temozolomide following radiotherapy as an effective strategy. The quality of life in the months and years after treatment is shaped profoundly by the anatomic region the tumor occupied. Many survivors contend with various forms of paralysis, speech impediments, difficulties with executive planning, and distorted sensory perception. Fortunately, a substantial portion of these deficits—particularly paralysis and speech difficulties—can be meaningfully rehabilitated through structured programs of speech therapy, occupational therapy, physical therapy, and vision therapy. The interplay between surgical extent, radiation delivery, and the brain region involved thus determines not only survival but the functional landscape in which patients rebuild their daily lives.
Prognosis & Long-term Outlook
The age-standardized five-year relative survival rate for anaplastic astrocytoma stands at 23.6 percent, and affected individuals face a mortality risk roughly 46 times that of matched members of the general population. The typical median survival spans two to three years, and secondary progression to glioblastoma multiforme is a common trajectory. Age exerts a pronounced influence on early outcomes: when elderly patients are compared with young adults aged 15 to 40, the excess hazard ratio drops from 10.15 at one year to 1.85 by three years, indicating that the elderly are far more vulnerable in the first year after diagnosis, while the survival gap narrows considerably thereafter. Several factors have been associated with improved survival, including the use of radiation, younger age at diagnosis, female sex, receiving treatment after the year 2000, and the performance of surgery. Together, these variables underscore that prognosis is not a single fixed number but a dynamic interplay of biology, age, and the therapeutic era in which a patient is treated.
Gallery
Frequently Asked Questions
Who is Anaplastic astrocytoma?
It is a rare, aggressive brain tumor that once carried its own standalone name but is now officially classified as a WHO grade 3 IDH-mutated astrocytoma. In the United States, roughly 0.35 new cases per 100,000 people are diagnosed every year.
What are Anaplastic astrocytoma's powers/role?
Depending on where it lodges in the brain, it can produce localized deficits such as limb weakness, speech difficulty, or vision loss, alongside broader effects like personality shifts, persistent headaches, nausea, and seizures. The interval between the first noticeable symptom and a confirmed diagnosis can vary considerably from person to person.
Why is Anaplastic astrocytoma important?
With a Ki-67 proliferation index generally in the 5–10 percent range, it represents a critical middle step in astrocytic malignancy—more aggressive than grade 2 but not yet at the glioblastoma level. Its rarity and the mandatory IDH-mutation criterion in modern classification make it a key reference point in neuro-oncology staging and trial design.
What is Anaplastic astrocytoma's backstory?
The term was retired in the 2021 WHO CNS classification, which folded it into the broader category of 'astrocytoma, IDH-mutant, grade 3.' The old name still appears in older textbooks and legacy patient records, but it no longer functions as a separate diagnostic label in current clinical guidelines.
More in Types of cancer 1-21
Spotted an error? Know more?
Reader corrections go straight into our review queue. Suggest an edit · How this site is sourced